drugset / Trial / NCT06666166
SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the effectiveness and safety of SHR-A1811 combined with apatinib in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma and colorectal cancer.
Timeline
- Start
- 2024-12
- Primary completion
- 2028-07
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | — | Oral |
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | — | Intravenous |